SlideShare a Scribd company logo
OPHTHALMIC PRODUCTS
PhR.Nirmal Raj Marasine
Instructor
WHSA
• Definition:
• Ophthalmic preparations (eye preparations) are sterile, liquid,
semi-solid, or solid preparations that may contain one or more
active pharmaceutical ingredient intended for application to the
conjunctiva, the conjunctival sac or the eyelids.
• They are specialized dosage forms designed to be instilled onto
the external surface of the eye (topical), administered inside
(intraocular) or adjacent (periocular) to the eye or used in
conjunction with an ophthalmic device.
• The most commonly employed ophthalmic dosage forms are
solutions, suspensions, and ointments.
• The newest dosage forms for ophthalmic drug delivery are: gels,
gel-forming solutions, ocular inserts , intravitreal injections and
implants.
ADVANTAGE:
• They are easily administered by the nurse
• They are easily administered by the patient himself.
• They have the quick absorption and effect.
• less visual and systemic side effects.
• increased shelf life.
• better patient compliance.
DISADVANTAGES:
• The very short time the solution stays at the eye
surface.
• Its poor bioavailability.
• The instability of the dissolved drug.
•The necessity of using preservative.
Ideal ophthalmic delivery system
Following characteristics are required to optimize
ocular drug delivery system:
•Good corneal penetration.
•Prolong contact time with corneal tissue.
•Simplicity of instillation for the patient.
•Non irritative and comfortable form
•Appropriate rheological properties
12/23/2018 434 PHT Ophthalmic preparations 5
CLASSIFICATION OF OCULAR DRUG
DELIVERY SYSTEMS:
Topical eye drops:
-Solutions
- Suspensions
- Powders for
reconstitution
- Sol to gel systems
-Ointments
- Gels
- Ocular inserts
Eye drops
Eye drops Sterile aqueous or oily solution or
suspension of one or more active ingredients intended
for installation into the eye.
 Oily eye drops are seldom used and should be
prepared in sterile oil ex: oily drops of pilocarpine .
The particle size of suspension should be less than 10
μm
Eye lotions
Eye lotions Used in large volume to mechanically
remove foreign materials.
 Each container is used one time and not require to
add preservative.
Ex. Sodium bicarbonate eye lotion used in emergency
treatment of acid burns of the eye
Eye ointments
It is sterile semi-solid preparation of homogenous
appearance intended for application to the conjunctiva.
The ointment base is paraffin base has melting point
close to body temp.
Eye Suspensions
Eye suspensions are not commonly used as compared
to eye drops.
They are prepared only in those cases when the drug
is insoluble in the desired vehicle or unstable in liquid
form.
They are also used to produce the sustained action of
the preparation.
Formulation:
•1)Drug
•2)Preservative
•3)Sterilization
•4)Isotonicity
•5)Buffer
•6)Viscosity
•7)Container
•8)Label
1) Drugs-
These contains drugs of various categories including
antiseptic, anti-inflammatory agent, mydriatic or
miotic properties
2) Preservative-
Eye drop should be sterile and should contain
preservatives to avoid microbial contamination when
container is open.
The preservative for ophthalmic use includes
benzalkonium chloride, chlorbutanol, phenylmercuric
acetate, phenylmercuric nitrate etc.,
3)Sterilization- Eye drops are sterilized by autoclaving
at 121°C for 15 minutes or by bacteria filter to avoid
thermal degradation for example- preservative
chlorbutanol hydrolyzes at high temperature
4)Isotonicity- All the solutes including drug contribute
to the osmotic pressure of the eye drip, therefore
isotonicity of the formula should be calculated and it is
adjusted with sodium chloride, for example sodium
chloride 0.9% and boric acid 1.9& are iso-osmotic
5)Buffer
The buffer should be added to maintain balance
between comfort, solubility, stability and activity of
drug.
For example the hydrolysed chlorbutanol forms
hydrochloride acid making the drop acidic. Whereas
certain drug like pilocarpine hydrochloride are acidic
6)Viscosity
The size of the drop and its residence in eye depends
on viscosity of eye drops.
 Methyl cellulose, hydroxypropyl methycellulose and
polyvenyl alcohol are common viscosity inhancer
7) Container
The commonly used container for ophthalmic
solutions or suspension is multi-dose container(5ml,
10ml).
Glass container is supplied with sterile plastic
dropper. Plastic bottles are with built up nozzle.
8)Label
Not for injection. For external use only. Shake well
before use (if it is suspension)
DOSAGE FORMS APPLIED TO THE
EYE
Topical Administration
Solutions
Suspension
Emulsion
Ointment
Gel
Perfusion
Spray
Inserts
Intraocular drug delivery
Intraocular injection
Implant
Iontophoresis
Drug delivery routes
•Solutions
• Ophthalmic solutions are sterile solutions intended for
instillation in the eye. Included in this dosage form category
are solid preparations that, when reconstituted according to
the label instructions, result in a solution
• Solutions are Manufactured by dissolution of the active
ingredients and a portion of the excipients into all portion of
water.
• The sterilization of this solution done by heat or by sterilizing
Filtration through sterile depth or membrane filter media Into
a sterile receptacle.
• This sterile solution is then mixed with the additional
required Sterile components such as viscosity –imparting
agents, Preservatives and so and the solution is brought to
final Volume with additional sterile water
Disadvantages of eye solutions:
• The very short time the solution stays at the eye surface.The
retention of a solution in the eye is influenced by viscosity.
• Its poor bioavailability (a major portion i.e. 75% is lost via naso
lacrimal drainage).
Examples of topical eye solutions:
• Atropine sulphate eye drops.
• Pilocarpine eye drops .
• Silver nitrate eye drops.
• Zinc sulphate eye drops.
suspensions
•If the drug is not sufficiently soluble, it can be
formulated as a suspension.
•A suspension may also be desired to improve
stability, Bioavailability ,and efficacy.
•The major topical ophthalmic suspensions are the
steroid anti-inflammatory agents.
•An ophthalmic suspension should use the drug in a
microfine form; usually 95% or more of the particles
have a Diameter of 10µm or less.
Examples of eye suspension
• Prednisolone acetate suspension.
• Besifloxacin suspension.
• Blephamide suspension.
• Fluorometholone suspension
• Emulsions
• Topical ophthalmic emulsions generally are prepared by
dissolving or dispersing the active ingredient(s) into an oil
phase, adding suitable emulsifying and suspending agents and
mixing with water vigorously to form a uniform oil-in-water
emulsion. Each phase is typically sterilized prior to or during
charging into the mixing vessel.
Ointments
•Ophthalmic ointments must be sterile
•The ointment base selected for an ophthalmic
ointment must be nonirritating to the eye and must
permit the diffusion of the active ingredient
throughout the secretions bathing the eye.
•Ophthalmic ointments have a longer ocular contact
time when compared to many ophthalmic solutions
•One disadvantage to ophthalmic ointments is the
blurred vision that occurs as the ointment base melts
and is spread across the lens.
Example of ophthalmic ointment
•Chloramphenicol ointment.
•Tetracycline ointment.
•Hydrocortisone ointment.
Gels
• Ophthalmic gels are composed of mucoadhesive
polymers that provide localized delivery of an active
ingredient to the eye.
• Such polymers have a property known as
bioadhesion meaning attachment of a drug carrier to
a specific biological tissue.
• These polymers are able to extend the contact time
of the drug with the biological tissues and thereby
improve ocular bioavailability
Perfusion
• Continuous and constant perfusion of the eye with drug solutions can be
achieved by the use of ambulatory motor driven syringes that deliver drug
solutions through fine polyethylene tubing positioned in the conjunctival sac
• This system allows the use of a lower drug concentration than used in
conventional eye-drops, yet will produce the same potency. Side effects are
reduced and constant therapeutic action is maintained
Sprays
• Spray systems produce similar results to eye-drops in
terms of duration of drug action and side effects. Sprays
have several advantages over eye-drops:
1.a more uniform spread of drug can be achieved
2.precise instillation requiring less manual dexterity than
for eye-drop administration and is particularly useful
for treating patients with unsteady hand movements
3.contamination and eye injury due to eye-drop
application are avoided
4.spray delivery causes less reflex lacrimation.
5.Can be used by patients who have difficulty bending
their neck back to administer drops.
Ophthalmic inserts
are defined as sterile solid or semisolid preparations, with a thin,
flexible and multilayered structure, for insertion in the conjunctival sac.
Advantages:
• Increasing contact time and improving bioavailability.
• Providing a prolong drug release and thus a better efficacy.
• Reduction of adverse effects.
• Reduction of the number administrations and thus better patient
compliance.
•FOR EXAMPLE
• Lacrisert is a sterile ophthalmic insert use in the treatment of dry Eye
syndrome and is usually recommended for patients unable to obtain
symptomatic relief with artifical tear solutions.
• The insert is composed of 5 mg of Hydroxypropyl cellulose in a rod-
shaped form about 1.27 mm diameter by about 3.5 mm long.
Intraocular Dosage Forms
• They are Ophthalmic products that introduced into the interior structures
of the eye primarily during ocular surgery.
Intraocular Injections
• The ophthalmologist use available parental dosage forms to deliver Anti-
infective, corticosteroids, and anesthetic products to achieve higher
therapeutic concentrations intraoculary than can ordinarily Be achieved
by topical or systemic administration.
• FDA approved intraocular injection include miotics, viscoelastics and an
antiviral agent for intravitreal injection.
Intravitreal implant
• An intravitreal sterile implant containing ganciclovir or
antineoplastic agents is a tablet of ganciclovir with Magnesium
stearate and is coated to retard release with Polyvinyl alcohol
and ethylene vinyl acetate polymers.
Such that the device when surgically implanted in the Vitreous
cavity release drug over a 5 to8 month period .
Ocular iontophoresis:
• Iontophoresis is the process in which direct current drives ions into cells
or tissues.
• If the drug molecules carry a positive charge, they are driven into the
tissues at the anode; if negatively charged, at the cathode.
• Ocular iontophoresis offers a drug delivery system that is fast, painless,
safe, and results in the delivery of a high concentration of the drug to a
specific site.
• Iontophoresis is useful for the treatment of bacterial keratitis,
Iontophoretic application of antibiotics may enhance their bactericidal
activity and reduce the severity of disease
Liposomes
• Liposome's are microscopic and submicroscopic vesicles
consists of one or more concentric sphere of Lipid bilayers
separated by Water or aqueous buffer compartments.
Packaging:
• Eyedrops have been packaged almost entirely in plastic
dropper bottles (the Drop-Tainer® plastic dispenser).
• The main advantage of the Drop-Tainer are:
- convenience of use by the patient
- decreased contamination potential
- lower weight
- lower cost
• The plastic bottle and dispensing tip is made of low-density
polyethylene (LDPE) resin, which provides the necessary
flexibility and inertness.
• The cap is made of harder resin than the
bottle.
*Advantage of LDPE resin:
- Compatible with a very wide range of drugs and formulation components
*Disadvantage of LDPE resin:
- Sorption and permeability characteristics e.g. volatile preservatives such
as chlorobutanol
- Weight loss by water vapor transmission
- LDPE resin is translucent, if the drug is light sensitive, additional package
protection is required (using opacifying agent such as titanium dioxide)
-- LDPE resin sterilized by gamma irradiation or ethylene oxide
• A special plastic ophthalmic package made of polypropylene
is introduced. The bottle is filled then sterilized by steam
under pressure at 121°C.
• The glass bottle is made sterile by dry-heat or steam
autoclave sterilization.
• Amber glass is used for light-resistance.
Storage
Ophthalmic preparations should maintain their
integrity throughout their shelf-life when stored at
the temperature indicated on the label.
 Special storage recommendations or limitations are
indicated in individual monographs.
40

More Related Content

What's hot

Ophthalmic preparation
Ophthalmic preparationOphthalmic preparation
Ophthalmic preparation
Ravish Yadav
 
Liquid dosage form monophsaic
Liquid dosage form monophsaicLiquid dosage form monophsaic
Liquid dosage form monophsaic
SR drug laboratories
 
Parenteral formulations
Parenteral formulationsParenteral formulations
Parenteral formulations
Sayeda Salma S.A.
 
PARENTRAL DOSAGE FORM OR STERILE DOSAGE FORM
PARENTRAL DOSAGE FORM OR  STERILE DOSAGE FORMPARENTRAL DOSAGE FORM OR  STERILE DOSAGE FORM
PARENTRAL DOSAGE FORM OR STERILE DOSAGE FORM
avinash thalkari
 
eye drops.pptx
 eye drops.pptx eye drops.pptx
eye drops.pptx
SanjaySingh272469
 
Small volume parenterals
Small volume parenteralsSmall volume parenterals
OPTHALMIC PREPARATION
OPTHALMIC PREPARATIONOPTHALMIC PREPARATION
OPTHALMIC PREPARATION
PoojaPatra16
 
SYRUP.pdf
SYRUP.pdfSYRUP.pdf
SYRUP.pdf
BALASUNDARESAN M
 
Pharmaceutical aerosols
Pharmaceutical aerosolsPharmaceutical aerosols
Pharmaceutical aerosols
Virendra Vaishnav
 
Containers and closure system of parenterals.
Containers and closure system of parenterals.Containers and closure system of parenterals.
Containers and closure system of parenterals.
University Institute of Pharmaceutical Sciences
 
Ocular drug delivery system
Ocular drug delivery systemOcular drug delivery system
Ocular drug delivery system
slidenka
 
Packaging of Ophthalmic and parenteral products
Packaging of Ophthalmic and parenteral productsPackaging of Ophthalmic and parenteral products
Packaging of Ophthalmic and parenteral productsRfinDmelomaniac Abir
 
Evaluation of ophthalmic preparation
Evaluation of ophthalmic preparationEvaluation of ophthalmic preparation
Evaluation of ophthalmic preparation
Suneal Saini
 
Semi solid dosage forms
Semi solid dosage formsSemi solid dosage forms
Semi solid dosage forms
Iqra Zulfiqar Ali Rajput
 
Cold cream vanishing cream
Cold cream vanishing creamCold cream vanishing cream
Cold cream vanishing cream
Sachin Sharma
 
Liquid dosage forms krishna
Liquid dosage forms krishnaLiquid dosage forms krishna
Liquid dosage forms krishna
Krishna Kumar
 
PARENTERAL PRODUCTS
PARENTERAL PRODUCTSPARENTERAL PRODUCTS
PARENTERAL PRODUCTS
DRxKartikiBhandari
 
occular drug delivery system
occular drug delivery systemoccular drug delivery system
occular drug delivery system
pratiksha Pratiksha
 

What's hot (20)

Opthalmic preparation
Opthalmic preparationOpthalmic preparation
Opthalmic preparation
 
Ophthalmic preparation
Ophthalmic preparationOphthalmic preparation
Ophthalmic preparation
 
Liquid dosage form monophsaic
Liquid dosage form monophsaicLiquid dosage form monophsaic
Liquid dosage form monophsaic
 
Parenteral formulations
Parenteral formulationsParenteral formulations
Parenteral formulations
 
PARENTRAL DOSAGE FORM OR STERILE DOSAGE FORM
PARENTRAL DOSAGE FORM OR  STERILE DOSAGE FORMPARENTRAL DOSAGE FORM OR  STERILE DOSAGE FORM
PARENTRAL DOSAGE FORM OR STERILE DOSAGE FORM
 
eye drops.pptx
 eye drops.pptx eye drops.pptx
eye drops.pptx
 
Small volume parenterals
Small volume parenteralsSmall volume parenterals
Small volume parenterals
 
OPTHALMIC PREPARATION
OPTHALMIC PREPARATIONOPTHALMIC PREPARATION
OPTHALMIC PREPARATION
 
SYRUP.pdf
SYRUP.pdfSYRUP.pdf
SYRUP.pdf
 
Pharmaceutical aerosols
Pharmaceutical aerosolsPharmaceutical aerosols
Pharmaceutical aerosols
 
Containers and closure system of parenterals.
Containers and closure system of parenterals.Containers and closure system of parenterals.
Containers and closure system of parenterals.
 
Ocular drug delivery system
Ocular drug delivery systemOcular drug delivery system
Ocular drug delivery system
 
Packaging of Ophthalmic and parenteral products
Packaging of Ophthalmic and parenteral productsPackaging of Ophthalmic and parenteral products
Packaging of Ophthalmic and parenteral products
 
Evaluation of ophthalmic preparation
Evaluation of ophthalmic preparationEvaluation of ophthalmic preparation
Evaluation of ophthalmic preparation
 
Semi solid dosage forms
Semi solid dosage formsSemi solid dosage forms
Semi solid dosage forms
 
Cold cream vanishing cream
Cold cream vanishing creamCold cream vanishing cream
Cold cream vanishing cream
 
Liquid dosage forms krishna
Liquid dosage forms krishnaLiquid dosage forms krishna
Liquid dosage forms krishna
 
PARENTERAL PRODUCTS
PARENTERAL PRODUCTSPARENTERAL PRODUCTS
PARENTERAL PRODUCTS
 
Alcohol content
Alcohol contentAlcohol content
Alcohol content
 
occular drug delivery system
occular drug delivery systemoccular drug delivery system
occular drug delivery system
 

Similar to Opthalmic product copy

Opthalmic Dr.pptx
Opthalmic Dr.pptxOpthalmic Dr.pptx
Opthalmic Dr.pptx
Dr. Samia
 
eye drop and ointment.ppt
eye drop and ointment.ppteye drop and ointment.ppt
eye drop and ointment.ppt
KoushalDhamija1
 
Opthalmic route of administration
Opthalmic route of administrationOpthalmic route of administration
Opthalmic route of administration
SANDEEP MEWADA
 
ophthalmic products
 ophthalmic products ophthalmic products
ophthalmic products
Md. Mynul Hasan
 
Introduction to ophthalmic drug delivary system .pptx
Introduction to ophthalmic drug delivary system .pptxIntroduction to ophthalmic drug delivary system .pptx
Introduction to ophthalmic drug delivary system .pptx
Harshadaa bafna
 
Ophthalmic preparations.pptx
Ophthalmic preparations.pptxOphthalmic preparations.pptx
Ophthalmic preparations.pptx
HebaYassin10
 
Ophthalmic Products
Ophthalmic ProductsOphthalmic Products
Ophthalmic Products
Imran Nur Manik
 
OPTHALMIC PRODUCTS.pptx
OPTHALMIC PRODUCTS.pptxOPTHALMIC PRODUCTS.pptx
OPTHALMIC PRODUCTS.pptx
bharatibakde1
 
Opthalmic preparation
Opthalmic preparationOpthalmic preparation
Opthalmic preparation
ibrahimussa
 
35980Lecture 3.ppt
35980Lecture 3.ppt35980Lecture 3.ppt
35980Lecture 3.ppt
VKJoshi4
 
Ophthalmic Preparation.pptx
Ophthalmic Preparation.pptxOphthalmic Preparation.pptx
Ophthalmic Preparation.pptx
DEBASISSEN10
 
Formulation of eye lotions
Formulation of eye lotions Formulation of eye lotions
Formulation of eye lotions
Dheeraj Saini
 
Ophthalmics
OphthalmicsOphthalmics
Ophthalmics
sukantsatapathy
 
Formulation of eye lotions
Formulation of eye lotions Formulation of eye lotions
Formulation of eye lotions
Dheeraj Saini
 
Special solution-and-suspension
Special solution-and-suspensionSpecial solution-and-suspension
Special solution-and-suspension
Cristina Joy Reyes
 
Sterile dosage form (opthalmic)
Sterile dosage form (opthalmic)Sterile dosage form (opthalmic)
Sterile dosage form (opthalmic)
Anil Deore
 
Ophthalmic Preparation
Ophthalmic Preparation Ophthalmic Preparation
Ophthalmic Preparation
Nandakishor Bhaurao Deshmukh
 
ocular solid dosge form.ppt
ocular solid dosge form.pptocular solid dosge form.ppt
ocular solid dosge form.ppt
amal860239
 
Ocular dds
Ocular ddsOcular dds
Ocular dds
Mithun Maniyar
 
Solutions
SolutionsSolutions
Solutions
sadhnalaljee
 

Similar to Opthalmic product copy (20)

Opthalmic Dr.pptx
Opthalmic Dr.pptxOpthalmic Dr.pptx
Opthalmic Dr.pptx
 
eye drop and ointment.ppt
eye drop and ointment.ppteye drop and ointment.ppt
eye drop and ointment.ppt
 
Opthalmic route of administration
Opthalmic route of administrationOpthalmic route of administration
Opthalmic route of administration
 
ophthalmic products
 ophthalmic products ophthalmic products
ophthalmic products
 
Introduction to ophthalmic drug delivary system .pptx
Introduction to ophthalmic drug delivary system .pptxIntroduction to ophthalmic drug delivary system .pptx
Introduction to ophthalmic drug delivary system .pptx
 
Ophthalmic preparations.pptx
Ophthalmic preparations.pptxOphthalmic preparations.pptx
Ophthalmic preparations.pptx
 
Ophthalmic Products
Ophthalmic ProductsOphthalmic Products
Ophthalmic Products
 
OPTHALMIC PRODUCTS.pptx
OPTHALMIC PRODUCTS.pptxOPTHALMIC PRODUCTS.pptx
OPTHALMIC PRODUCTS.pptx
 
Opthalmic preparation
Opthalmic preparationOpthalmic preparation
Opthalmic preparation
 
35980Lecture 3.ppt
35980Lecture 3.ppt35980Lecture 3.ppt
35980Lecture 3.ppt
 
Ophthalmic Preparation.pptx
Ophthalmic Preparation.pptxOphthalmic Preparation.pptx
Ophthalmic Preparation.pptx
 
Formulation of eye lotions
Formulation of eye lotions Formulation of eye lotions
Formulation of eye lotions
 
Ophthalmics
OphthalmicsOphthalmics
Ophthalmics
 
Formulation of eye lotions
Formulation of eye lotions Formulation of eye lotions
Formulation of eye lotions
 
Special solution-and-suspension
Special solution-and-suspensionSpecial solution-and-suspension
Special solution-and-suspension
 
Sterile dosage form (opthalmic)
Sterile dosage form (opthalmic)Sterile dosage form (opthalmic)
Sterile dosage form (opthalmic)
 
Ophthalmic Preparation
Ophthalmic Preparation Ophthalmic Preparation
Ophthalmic Preparation
 
ocular solid dosge form.ppt
ocular solid dosge form.pptocular solid dosge form.ppt
ocular solid dosge form.ppt
 
Ocular dds
Ocular ddsOcular dds
Ocular dds
 
Solutions
SolutionsSolutions
Solutions
 

More from nirmal marasine

Heat process
Heat processHeat process
Heat process
nirmal marasine
 
Drying final
Drying finalDrying final
Drying final
nirmal marasine
 
Size reduction f copy
Size reduction f   copySize reduction f   copy
Size reduction f copy
nirmal marasine
 
Aerosol
AerosolAerosol
Pharmacceutical packaging
Pharmacceutical packagingPharmacceutical packaging
Pharmacceutical packaging
nirmal marasine
 
Surgical products
Surgical productsSurgical products
Surgical products
nirmal marasine
 
Powders
PowdersPowders
Diuretics by nirmal raj marasine
Diuretics by nirmal raj marasine Diuretics by nirmal raj marasine
Diuretics by nirmal raj marasine
nirmal marasine
 

More from nirmal marasine (8)

Heat process
Heat processHeat process
Heat process
 
Drying final
Drying finalDrying final
Drying final
 
Size reduction f copy
Size reduction f   copySize reduction f   copy
Size reduction f copy
 
Aerosol
AerosolAerosol
Aerosol
 
Pharmacceutical packaging
Pharmacceutical packagingPharmacceutical packaging
Pharmacceutical packaging
 
Surgical products
Surgical productsSurgical products
Surgical products
 
Powders
PowdersPowders
Powders
 
Diuretics by nirmal raj marasine
Diuretics by nirmal raj marasine Diuretics by nirmal raj marasine
Diuretics by nirmal raj marasine
 

Recently uploaded

LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
DanBrown980551
 
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
James Anderson
 
GraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge GraphGraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge Graph
Guy Korland
 
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdfFIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance
 
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Ramesh Iyer
 
UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4
DianaGray10
 
DevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA ConnectDevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA Connect
Kari Kakkonen
 
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
Product School
 
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024
Tobias Schneck
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance
 
Securing your Kubernetes cluster_ a step-by-step guide to success !
Securing your Kubernetes cluster_ a step-by-step guide to success !Securing your Kubernetes cluster_ a step-by-step guide to success !
Securing your Kubernetes cluster_ a step-by-step guide to success !
KatiaHIMEUR1
 
How world-class product teams are winning in the AI era by CEO and Founder, P...
How world-class product teams are winning in the AI era by CEO and Founder, P...How world-class product teams are winning in the AI era by CEO and Founder, P...
How world-class product teams are winning in the AI era by CEO and Founder, P...
Product School
 
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdfSmart TV Buyer Insights Survey 2024 by 91mobiles.pdf
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf
91mobiles
 
To Graph or Not to Graph Knowledge Graph Architectures and LLMs
To Graph or Not to Graph Knowledge Graph Architectures and LLMsTo Graph or Not to Graph Knowledge Graph Architectures and LLMs
To Graph or Not to Graph Knowledge Graph Architectures and LLMs
Paul Groth
 
Elevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object CalisthenicsElevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object Calisthenics
Dorra BARTAGUIZ
 
The Future of Platform Engineering
The Future of Platform EngineeringThe Future of Platform Engineering
The Future of Platform Engineering
Jemma Hussein Allen
 
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
Product School
 
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Jeffrey Haguewood
 
Epistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI supportEpistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI support
Alan Dix
 
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered Quality
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualitySoftware Delivery At the Speed of AI: Inflectra Invests In AI-Powered Quality
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered Quality
Inflectra
 

Recently uploaded (20)

LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...
 
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
 
GraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge GraphGraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge Graph
 
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdfFIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
FIDO Alliance Osaka Seminar: Passkeys at Amazon.pdf
 
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...
 
UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4UiPath Test Automation using UiPath Test Suite series, part 4
UiPath Test Automation using UiPath Test Suite series, part 4
 
DevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA ConnectDevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA Connect
 
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
AI for Every Business: Unlocking Your Product's Universal Potential by VP of ...
 
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
 
Securing your Kubernetes cluster_ a step-by-step guide to success !
Securing your Kubernetes cluster_ a step-by-step guide to success !Securing your Kubernetes cluster_ a step-by-step guide to success !
Securing your Kubernetes cluster_ a step-by-step guide to success !
 
How world-class product teams are winning in the AI era by CEO and Founder, P...
How world-class product teams are winning in the AI era by CEO and Founder, P...How world-class product teams are winning in the AI era by CEO and Founder, P...
How world-class product teams are winning in the AI era by CEO and Founder, P...
 
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdfSmart TV Buyer Insights Survey 2024 by 91mobiles.pdf
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf
 
To Graph or Not to Graph Knowledge Graph Architectures and LLMs
To Graph or Not to Graph Knowledge Graph Architectures and LLMsTo Graph or Not to Graph Knowledge Graph Architectures and LLMs
To Graph or Not to Graph Knowledge Graph Architectures and LLMs
 
Elevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object CalisthenicsElevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object Calisthenics
 
The Future of Platform Engineering
The Future of Platform EngineeringThe Future of Platform Engineering
The Future of Platform Engineering
 
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
De-mystifying Zero to One: Design Informed Techniques for Greenfield Innovati...
 
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...
 
Epistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI supportEpistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI support
 
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered Quality
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualitySoftware Delivery At the Speed of AI: Inflectra Invests In AI-Powered Quality
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered Quality
 

Opthalmic product copy

  • 1. OPHTHALMIC PRODUCTS PhR.Nirmal Raj Marasine Instructor WHSA
  • 2. • Definition: • Ophthalmic preparations (eye preparations) are sterile, liquid, semi-solid, or solid preparations that may contain one or more active pharmaceutical ingredient intended for application to the conjunctiva, the conjunctival sac or the eyelids. • They are specialized dosage forms designed to be instilled onto the external surface of the eye (topical), administered inside (intraocular) or adjacent (periocular) to the eye or used in conjunction with an ophthalmic device. • The most commonly employed ophthalmic dosage forms are solutions, suspensions, and ointments. • The newest dosage forms for ophthalmic drug delivery are: gels, gel-forming solutions, ocular inserts , intravitreal injections and implants.
  • 3. ADVANTAGE: • They are easily administered by the nurse • They are easily administered by the patient himself. • They have the quick absorption and effect. • less visual and systemic side effects. • increased shelf life. • better patient compliance.
  • 4. DISADVANTAGES: • The very short time the solution stays at the eye surface. • Its poor bioavailability. • The instability of the dissolved drug. •The necessity of using preservative.
  • 5. Ideal ophthalmic delivery system Following characteristics are required to optimize ocular drug delivery system: •Good corneal penetration. •Prolong contact time with corneal tissue. •Simplicity of instillation for the patient. •Non irritative and comfortable form •Appropriate rheological properties 12/23/2018 434 PHT Ophthalmic preparations 5
  • 6. CLASSIFICATION OF OCULAR DRUG DELIVERY SYSTEMS: Topical eye drops: -Solutions - Suspensions - Powders for reconstitution - Sol to gel systems -Ointments - Gels - Ocular inserts
  • 7. Eye drops Eye drops Sterile aqueous or oily solution or suspension of one or more active ingredients intended for installation into the eye.  Oily eye drops are seldom used and should be prepared in sterile oil ex: oily drops of pilocarpine . The particle size of suspension should be less than 10 μm
  • 8. Eye lotions Eye lotions Used in large volume to mechanically remove foreign materials.  Each container is used one time and not require to add preservative. Ex. Sodium bicarbonate eye lotion used in emergency treatment of acid burns of the eye
  • 9. Eye ointments It is sterile semi-solid preparation of homogenous appearance intended for application to the conjunctiva. The ointment base is paraffin base has melting point close to body temp.
  • 10. Eye Suspensions Eye suspensions are not commonly used as compared to eye drops. They are prepared only in those cases when the drug is insoluble in the desired vehicle or unstable in liquid form. They are also used to produce the sustained action of the preparation.
  • 11.
  • 13. 1) Drugs- These contains drugs of various categories including antiseptic, anti-inflammatory agent, mydriatic or miotic properties 2) Preservative- Eye drop should be sterile and should contain preservatives to avoid microbial contamination when container is open. The preservative for ophthalmic use includes benzalkonium chloride, chlorbutanol, phenylmercuric acetate, phenylmercuric nitrate etc.,
  • 14. 3)Sterilization- Eye drops are sterilized by autoclaving at 121°C for 15 minutes or by bacteria filter to avoid thermal degradation for example- preservative chlorbutanol hydrolyzes at high temperature 4)Isotonicity- All the solutes including drug contribute to the osmotic pressure of the eye drip, therefore isotonicity of the formula should be calculated and it is adjusted with sodium chloride, for example sodium chloride 0.9% and boric acid 1.9& are iso-osmotic
  • 15. 5)Buffer The buffer should be added to maintain balance between comfort, solubility, stability and activity of drug. For example the hydrolysed chlorbutanol forms hydrochloride acid making the drop acidic. Whereas certain drug like pilocarpine hydrochloride are acidic 6)Viscosity The size of the drop and its residence in eye depends on viscosity of eye drops.  Methyl cellulose, hydroxypropyl methycellulose and polyvenyl alcohol are common viscosity inhancer
  • 16. 7) Container The commonly used container for ophthalmic solutions or suspension is multi-dose container(5ml, 10ml). Glass container is supplied with sterile plastic dropper. Plastic bottles are with built up nozzle. 8)Label Not for injection. For external use only. Shake well before use (if it is suspension)
  • 17. DOSAGE FORMS APPLIED TO THE EYE Topical Administration Solutions Suspension Emulsion Ointment Gel Perfusion Spray Inserts Intraocular drug delivery Intraocular injection Implant Iontophoresis
  • 19. •Solutions • Ophthalmic solutions are sterile solutions intended for instillation in the eye. Included in this dosage form category are solid preparations that, when reconstituted according to the label instructions, result in a solution • Solutions are Manufactured by dissolution of the active ingredients and a portion of the excipients into all portion of water. • The sterilization of this solution done by heat or by sterilizing Filtration through sterile depth or membrane filter media Into a sterile receptacle. • This sterile solution is then mixed with the additional required Sterile components such as viscosity –imparting agents, Preservatives and so and the solution is brought to final Volume with additional sterile water
  • 20. Disadvantages of eye solutions: • The very short time the solution stays at the eye surface.The retention of a solution in the eye is influenced by viscosity. • Its poor bioavailability (a major portion i.e. 75% is lost via naso lacrimal drainage). Examples of topical eye solutions: • Atropine sulphate eye drops. • Pilocarpine eye drops . • Silver nitrate eye drops. • Zinc sulphate eye drops.
  • 21. suspensions •If the drug is not sufficiently soluble, it can be formulated as a suspension. •A suspension may also be desired to improve stability, Bioavailability ,and efficacy. •The major topical ophthalmic suspensions are the steroid anti-inflammatory agents. •An ophthalmic suspension should use the drug in a microfine form; usually 95% or more of the particles have a Diameter of 10µm or less.
  • 22. Examples of eye suspension • Prednisolone acetate suspension. • Besifloxacin suspension. • Blephamide suspension. • Fluorometholone suspension
  • 23. • Emulsions • Topical ophthalmic emulsions generally are prepared by dissolving or dispersing the active ingredient(s) into an oil phase, adding suitable emulsifying and suspending agents and mixing with water vigorously to form a uniform oil-in-water emulsion. Each phase is typically sterilized prior to or during charging into the mixing vessel.
  • 24. Ointments •Ophthalmic ointments must be sterile •The ointment base selected for an ophthalmic ointment must be nonirritating to the eye and must permit the diffusion of the active ingredient throughout the secretions bathing the eye. •Ophthalmic ointments have a longer ocular contact time when compared to many ophthalmic solutions •One disadvantage to ophthalmic ointments is the blurred vision that occurs as the ointment base melts and is spread across the lens.
  • 25. Example of ophthalmic ointment •Chloramphenicol ointment. •Tetracycline ointment. •Hydrocortisone ointment.
  • 26. Gels • Ophthalmic gels are composed of mucoadhesive polymers that provide localized delivery of an active ingredient to the eye. • Such polymers have a property known as bioadhesion meaning attachment of a drug carrier to a specific biological tissue. • These polymers are able to extend the contact time of the drug with the biological tissues and thereby improve ocular bioavailability
  • 27. Perfusion • Continuous and constant perfusion of the eye with drug solutions can be achieved by the use of ambulatory motor driven syringes that deliver drug solutions through fine polyethylene tubing positioned in the conjunctival sac • This system allows the use of a lower drug concentration than used in conventional eye-drops, yet will produce the same potency. Side effects are reduced and constant therapeutic action is maintained
  • 28. Sprays • Spray systems produce similar results to eye-drops in terms of duration of drug action and side effects. Sprays have several advantages over eye-drops: 1.a more uniform spread of drug can be achieved 2.precise instillation requiring less manual dexterity than for eye-drop administration and is particularly useful for treating patients with unsteady hand movements 3.contamination and eye injury due to eye-drop application are avoided 4.spray delivery causes less reflex lacrimation. 5.Can be used by patients who have difficulty bending their neck back to administer drops.
  • 29. Ophthalmic inserts are defined as sterile solid or semisolid preparations, with a thin, flexible and multilayered structure, for insertion in the conjunctival sac.
  • 30. Advantages: • Increasing contact time and improving bioavailability. • Providing a prolong drug release and thus a better efficacy. • Reduction of adverse effects. • Reduction of the number administrations and thus better patient compliance. •FOR EXAMPLE • Lacrisert is a sterile ophthalmic insert use in the treatment of dry Eye syndrome and is usually recommended for patients unable to obtain symptomatic relief with artifical tear solutions. • The insert is composed of 5 mg of Hydroxypropyl cellulose in a rod- shaped form about 1.27 mm diameter by about 3.5 mm long.
  • 31. Intraocular Dosage Forms • They are Ophthalmic products that introduced into the interior structures of the eye primarily during ocular surgery. Intraocular Injections • The ophthalmologist use available parental dosage forms to deliver Anti- infective, corticosteroids, and anesthetic products to achieve higher therapeutic concentrations intraoculary than can ordinarily Be achieved by topical or systemic administration. • FDA approved intraocular injection include miotics, viscoelastics and an antiviral agent for intravitreal injection.
  • 32. Intravitreal implant • An intravitreal sterile implant containing ganciclovir or antineoplastic agents is a tablet of ganciclovir with Magnesium stearate and is coated to retard release with Polyvinyl alcohol and ethylene vinyl acetate polymers. Such that the device when surgically implanted in the Vitreous cavity release drug over a 5 to8 month period .
  • 33. Ocular iontophoresis: • Iontophoresis is the process in which direct current drives ions into cells or tissues. • If the drug molecules carry a positive charge, they are driven into the tissues at the anode; if negatively charged, at the cathode. • Ocular iontophoresis offers a drug delivery system that is fast, painless, safe, and results in the delivery of a high concentration of the drug to a specific site. • Iontophoresis is useful for the treatment of bacterial keratitis, Iontophoretic application of antibiotics may enhance their bactericidal activity and reduce the severity of disease
  • 34. Liposomes • Liposome's are microscopic and submicroscopic vesicles consists of one or more concentric sphere of Lipid bilayers separated by Water or aqueous buffer compartments.
  • 35. Packaging: • Eyedrops have been packaged almost entirely in plastic dropper bottles (the Drop-Tainer® plastic dispenser). • The main advantage of the Drop-Tainer are: - convenience of use by the patient - decreased contamination potential - lower weight - lower cost • The plastic bottle and dispensing tip is made of low-density polyethylene (LDPE) resin, which provides the necessary flexibility and inertness. • The cap is made of harder resin than the bottle.
  • 36. *Advantage of LDPE resin: - Compatible with a very wide range of drugs and formulation components *Disadvantage of LDPE resin: - Sorption and permeability characteristics e.g. volatile preservatives such as chlorobutanol - Weight loss by water vapor transmission - LDPE resin is translucent, if the drug is light sensitive, additional package protection is required (using opacifying agent such as titanium dioxide) -- LDPE resin sterilized by gamma irradiation or ethylene oxide
  • 37. • A special plastic ophthalmic package made of polypropylene is introduced. The bottle is filled then sterilized by steam under pressure at 121°C.
  • 38. • The glass bottle is made sterile by dry-heat or steam autoclave sterilization. • Amber glass is used for light-resistance.
  • 39. Storage Ophthalmic preparations should maintain their integrity throughout their shelf-life when stored at the temperature indicated on the label.  Special storage recommendations or limitations are indicated in individual monographs.
  • 40. 40